Hippocampal adult neurogenesis is enhanced by chronic eszopiclone treatment in rats.
The adult hippocampal dentate gyrus (DG) exhibits cell proliferation and neurogenesis throughout life. We examined the effects of daily administration of eszopiclone (Esz), a commonly used hypnotic drug and gamma-aminobutyric acid (GABA) agonist, compared with vehicle, on DG cell proliferation and neurogenesis, and on sleep-wake patterns. Esz was administered during the usual sleep period of rats, to mimic typical use in humans. Esz treatment for 7 days did not affect the rate of cell proliferation, as measured by 5-bromo-2'-deoxyuridine (BrdU) immunostaining. However, twice-daily Esz administration for 2 weeks increased survival of newborn cells by 46%. Most surviving cells exhibited a neuronal phenotype, identified as BrdU-neuronal nuclei (NeuN) double-labeling. NeuN is a marker of neurons. Non-rapid eye movement sleep was increased on day 1, but not on days 7 or 14 of Esz administration. Delta electroencephalogram activity was increased on days 1 and 7 of treatment, but not on day 14. There is evidence that enhancement of DG neurogenesis is a critical component of the effects of antidepressant treatments of major depressive disorder (MDD). Adult-born DG cells are responsive to GABAergic stimulation, which promotes cell maturation. The present study suggests that Esz, presumably acting as a GABA agonist, has pro-neurogenic effects in the adult DG. This result is consistent with evidence that Esz enhances the antidepressant treatment response of patients with MDD with insomnia.
Methippara
Melvi
M
Department of Psychology, UCLA, Los Angeles, CA, USA.
Bashir
Tariq
T
Suntsova
Natalia
N
Szymusiak
Ron
R
McGinty
Dennis
D
D000818:Animals; D053961:Azabicyclo Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D002452:Cell Count; D002470:Cell Survival / Q000187:drug effects; D000069582:Eszopiclone; D006624:Hippocampus / Q000166:cytology / Q000187:drug effects* / Q000254:growth & development; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D055495:Neurogenesis / Q000187:drug effects*; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012890:Sleep / Q000187:drug effects; D013997:Time Factors
D053961:Azabicyclo Compounds; D006993:Hypnotics and Sedatives; D010879:Piperazines; D000069582:Eszopiclone
Biol Psychiatry. 2006 Jun 15;59(12):1136-43
16797263
Sleep. 2008 Jul;31(7):1043-51
18652100
BMC Psychiatry. 2007 Aug 21;7:42
17711589
J Neurophysiol. 2005 Dec;94(6):4224-33
16014798
Psychopharmacology (Berl). 1997 Mar;130(2):139-43
9106911
Biol Psychiatry. 2006 Jun 1;59(11):1052-60
16581036
Nature. 2006 Feb 2;439(7076):589-93
16341203
Anesth Analg. 2008 Jun;106(6):1772-7
18499608
Eur J Neurosci. 2005 Oct;22(8):2111-6
16262649
Science. 2003 Aug 8;301(5634):805-9
12907793
Int J Neuropsychopharmacol. 2010 Jul;13(6):759-74
19775499
Sleep. 2007 Aug;30(8):959-68
17702264
Mol Cell Neurosci. 2005 Jun;29(2):181-9
15911343
J Neurosci. 2000 Dec 15;20(24):9104-10
11124987
Anat Rec. 1991 Dec;231(4):482-97
1793176
Neuron. 2005 Sep 15;47(6):803-15
16157276
J Neurosci. 1992 Sep;12(9):3642-50
1527603
Nat Rev Neurosci. 2006 Mar;7(3):179-93
16495940
Brain Res. 2005 Dec 14;1065(1-2):53-9
16309630
Neuroscience. 2007 Oct 26;149(2):273-85
17900815
Am J Physiol Regul Integr Comp Physiol. 2008 May;294(5):R1693-703
18287218
Sleep. 2003 Nov 1;26(7):793-9
14655910
Ann N Y Acad Sci. 2007 Jan;1096:157-69
17405927
J Neurophysiol. 2005 Dec;94(6):4528-32
16033936
Brain Res. 2008 Sep 4;1228:14-9
18616933
Biol Psychiatry. 2007 Mar 15;61(6):806-12
17210135
Am J Psychiatry. 2003 Mar;160(3):577-9
12611844
J Med Chem. 2008 Nov 27;51(22):7243-52
18973287
J Clin Sleep Med. 2007 Feb 15;3(1):48-55
17557453
Nat Rev Neurosci. 2002 Sep;3(9):728-39
12209121
Arch Gen Psychiatry. 2007 Feb;64(2):193-200
17283286
J Neurosci. 2007 Mar 21;27(12):3252-9
17376985
Brain Res. 2009 Mar 9;1259:26-31
19138676
Am J Psychiatry. 2002 Apr;159(4):663-5
11925309
Nat Neurosci. 2007 Sep;10(9):1110-5
17726477
Neuroscience. 1994 Jul;61(2):203-9
7969902
JAMA. 1989 Sep 15;262(11):1479-84
2769898
Arch Gen Psychiatry. 2004 Jul;61(7):705-13
15237082
Neuroscience. 2005;134(3):721-3
16054767
Annu Rev Neurosci. 2005;28:223-50
16022595
Neuropharmacology. 2009 May-Jun;56(6-7):994-1000
19217915
J Neuroendocrinol. 2002 May;14(5):397-402
12000545
Trends Neurosci. 2004 Aug;27(8):447-52
15271491
Int J Neuropsychopharmacol. 2009 Nov;12(10):1421-8
19775501
Sleep. 2008 Feb;31(2):259-70
18274274
Curr Opin Neurobiol. 2004 Apr;14(2):186-91
15082323
Neuroscience. 2007 Aug 10;148(1):325-33
17630219
Mol Psychiatry. 2000 May;5(3):262-9
10889528
Arch Gen Psychiatry. 2002 Jun;59(6):521-9
12044194
Nat Med. 1998 Nov;4(11):1313-7
9809557
J Pharmacol Sci. 2004 Mar;94(3):246-51
15037809
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17501-6
17088541
J Comp Neurol. 2001 Jul 9;435(4):406-17
11406822
Arch Gen Psychiatry. 1999 Nov;56(11):1043-7
10565505
Am J Psychiatry. 2004 Feb;161(2):368-70
14754790
Hippocampus. 2006;16(3):296-304
16411241
Neurobiol Aging. 2005 Jan;26(1):103-14
15585350
Int J Neuropsychopharmacol. 2008 Mar;11(2):255-60
17625025
Eur J Neurosci. 2009 Jan;29(2):244-52
19200231